that legendary voice may never be heard again in public. releasing a statement saying the progressive disease has made it impossible to sing and not easy to speak, but it will take a lot more than als to silence this icon. certainly right. several number one hits in the 70s including the song you just heard killing me softly. also released 20 studio albums, won four grammys and a career that spanned more than five decades. what a voice. the most amazing duo back in the 70s, donny hathaway. s the voice sadly gone as well and died, you know, decades ago, but still, wow. what a voice. what a voice. what a woman. jut takes you back when you listen to this. also, update on jay leno. recovering this morning from burn injuries following a gasoline fire in his garage over the weekend. stephanie elam joins us from los angeles. is he going to be okay?
of the highest on record. it masked to certain cancers. the case that you just show it was one of lung cancer, and that was down at 50%, and that is a very fast cancer. bowel cancer is the worst on record in september, it is down below 40%. this is mostly diagnostic delays, so talked about reporting. you might actually have the scan, but you re still waiting for a radiologist or a similar clinician s report, so it fundamentally comes down to workforce. at the root of it, we all know that cancer is a progressive disease, but for each four week delay, the best evidence suggests there is a vector 60% increase in your 6% increase on your chance of dying. ii your 696 increase on your chance of d inc. , ., your 696 increase on your chance ofd inc. ., ., , .,
medic responses in three of nine patients and subsequently in the combination study with immunotherapy, we saw the patients who had previously had progressive disease and receiving the same sorts of immunotherapies, a number of those patients had substantial responses of their disease. this is encouraging data which points the way to further trials. ., , ,., , ., trials. and at this point, you know who trials. and at this point, you know who it trials. and at this point, you know who it could trials. and at this point, you know who it could help, - trials. and at this point, you | know who it could help, what kind of patients. the know who it could help, what kind of patients. kind of patients. the initial tar: ets kind of patients. the initial targets for kind of patients. the initial targets for patients - kind of patients. the initial targets for patients are - targets for patients are various types of skin cancers, but also patients with head and neck cancers, this is an
cancers. so we put in genes that would simile the bodies immune system, to fight cancer, and we also put in the ability of that virus to manufacture and immunotherapy drug inside the cancer itself, so rather than having to give that drug as an injection of the virus makes it for us within the tumour, and so we treated patients with direct injections into the tumours, initially just with the verizon injections into the tumours, initiallyjust with the verizon its own, and then with the virus plus a standard immunotherapy. and in the first phase we saw dramatic responses in three of the nine patients, and in the study with immunotherapy, we saw the patients who previously had progressive disease when receiving those same therapies, a number of those patients had substantial responses of their disease, so this is encouraging data that really points the way to further trials. find encouraging data that really points the way to further trials. the way to further trials. and at this point.